Clinical utility of testing human immunodeficiency virus for drug resistance

Clinical Infectious Diseases

Volumn 30, Issue SUPPL. 2, 2000, Pages

  Harrigan, P R ^a   Cote H C F ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; CONFERENCE PAPER; DRUG RESEARCH; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS; MONITORING; PHENOTYPE; PRIORITY JOURNAL;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PATIENT CARE MANAGEMENT; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034455664     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313861     Document Type: Conference Paper

References (60)

1. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription
2. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
3. Clinical significance of drug resistance in HIV-1 infection
4. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase
5. Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: The potential to use resistance data to guide clinical decisions
6. Virologic resistance to efavirenz
7. Genotypic and phenotypic correlates of response to abacavir (ABC, 1592)
8. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development
9. Highly mutated RT and protease are common in clinically failing patients failing multiple combination therapies
10. Sequence clusters in human immunodeficiency virus type I reverse transcriptase are associated with subsequent virological response to antiretroviral therapy
11. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: Association with therapy failure
12. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: Immunologic and virologic responses to zidovudine
13. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
14. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
15. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of the International AIDS Society-USA Panel
16. Mutations in retroviral genes associated with drug resistance
17. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy
18. Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis
19. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database
20. Genotypic or phenotypic susceptibility testing may not predict clinical response to indinavir
21. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy
22. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates
23. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
24. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation with virologic outcome
25. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
26. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus 2′,3′-dideoxycytidine combination therapy
27. Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: Comparison with sequence analysis
28. Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy
29. A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC)
30. A novel cell-based approach for analysing the drug sensitivity of primary HIV-1 isolates
31. Viral resistance and the selection of antiretroviral combinations
32. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment
33. Phenotypic HIV resistance in vitro correlates with viral load response to abacavir (1592, ABC) in vivo
34. Genotypic analysis for resistance testing (GART) as a clinical tool: A retrospective analysis
35. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program
36. Baseline HIV drug resistance profile predicts response to ritonavir/saquinavir protease inhibitor therapy in a community setting
37. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
38. Impact of drug resistance mutations on virologic response to salvage therapy
39. Multi-drug rescue therapy (MDRT) for HIV-infected individuals with prior virologic failure to multiple regimens
40. + outcome following genotypic antiretroviral resistance testing (GART) in primary care setting in Atlanta, Georgia
41. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
42. Final results of CPCRA 046: A pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy
43. Phenotypic resistance testing significantly improves response to therapy (Tx): A randomized trial (VIRA 3001)
44. Antiretroviral drug resistance testing to support the clinical care of patients with HIV/AIDS
45. Predictors of success of antiretroviral therapy (ART) in a prospective clinic cohort
46. Drug-resistant HIV-1: The virus strikes back
47. Public health implications of antiretroviral therapy and HIV drug resistance
48. Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1
49. Primary lamivudine resistance in acute HIV infection
50. Genotypic resistance in treatment-naive patients
51. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine
52. Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients
53. Detection of genotypic drug resistance to antiviral nucleoside inhibitors in short-time pretreated and drug-naive HIV-1 infected patients as predictor of treatment failure in high acting retroviral therapy (HAART)
54. Patterns of phenotypic and genotypic cross-resistance among protease inhibitors in over 1,000 clinical HIV-1 isolates
55. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
56. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
57. Detection of mutations in the HIV-1 reverse transcriptase (RT) gene and its predictive value at the start of antiretroviral therapy
58. HIV-1 drug resistance in newly infected individuals
59. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
60. Impact of moderate decreases in baseline NNRT1 susceptibility on response to antiretroviral therapy